1,721,292 research outputs found
Cytotoxic T Lymphocytes (CTLs) and Kidney Transplantation: An Overview
No full textInvolvement of T lymphocytes in kidney transplantation is a well-developed topic; however, most of the scientific interest focused on the different type of CD4+ lymphocyte subpopulations. Few authors, instead, investigated the role of CD8+ T cells in renal transplantation and how deleterious they can be to long-term allograft survival. Recently, there has been a renewed interest in the CD8+ T cells involvement in the transplantation field with the aim to investigate the immunological mechanisms underlying the infiltration of CD8+ T cells and their biological functions in human kidney allografts. The purpose of the present review is to highlight the role of allo-reactive cytotoxic T lymphocytes (CTLs) CD8+ subset in allograft kidney recipients and their related clinical complications
Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Colucci G, Manno C, Grandaliano G, Schena FP. Clin Nephrol. 2011 Apr;75(4):374-9
No full textAKT activation may represent the molecular link between rapamycin (RAPA) treatment and insulin-resistance in renal transplant recipients.
No full textAssociation of chronic microinflammation, progression of atherosclerosis and outcome in maintenance hemodialysis (HD):lond term effects of dialitic membranes
No full textLow serum fetuin-a levels are associated with an higher cardiovascular morbidity and mortality risk in hemodialysis patients
No full text
Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression
No full textThe incidence of Kaposi’s sarcoma (KS) among the recipients of solid organ
transplants is about 500 times the rate in the general population, suggesting a
role for immunosuppression in the development of the disease. The drugs used
for the induction and maintenance of immunosuppression and the length of
treatment with these agents influence both the incidence and the type of cancer
development. The clinical presentation of KS in transplant recipients is often
limited to the skin. The risk of death from KS is related to the form and extent
of the lesions. The main approach to managing transplant-associated KS is to
reduce or even discontinue immunosuppressive therapy; this strategy carries a
risk of acute rejection of the graft. KS is a multicentric tumor composed of
endothelium-lined vascular spaces and spindle-shaped cells. Its pathogenesis is
unclear. Recent evidence suggests that vascular endothelial growth factor
(VEGF) is likely to be a growth factor for KS cells: blocking the interaction
between VEGF and Flk-1/KDR can abolish VEGF-induced growth of the
tumor. Recently, Sirolimus, a drug used in kidney-transplant recipients, has
been suggested to reduce KS progression in transplant recipients. This unexpected
effect of the drug confirms previous experimental information on KS
pathogenesis and may shed light on an array of molecular mechanisms, modulated
by Sirolimus, of potential clinical interest in the transplantation scenario
Management of side effects of sirolimus therapy
No full textSirolimus (SRL) has been shown to improve long-term graft survival in several calcineurin inhibitor avoidance/minimization protocols. Although SRL has been suggested to reduce the progression of chronic renal graft damage and to prevent the development of neoplasia, two of the most prominent challenges in the field of transplantation, its use is significantly limited by an extremely high incidence of side effects. Some of the side effects are directly linked to the antiproliferative action of SRL, whereas the mechanisms underlying most of the undesired effects of the drug are still far from being clarified. Nevertheless, there is an increasing body of evidence linking most these drug-associated events to SRL dose. In addition, it is now possible to identify well-defined risk factors for most of these effects. Thus, to limit SRL-related side effects the two golden rules are (1) accurate selection of patients to be treated and (2) avoidance of high SRL doses
- …
